Published September 26, 2008 | Version v1
Journal article

GS143, an IκB ubiquitination inhibitor, inhibits allergic airway inflammation in mice

  • 1. Department of Allergy and Clinical Immunology, Chiba University Hospital (Japan)
  • 2. Department of Molecular Genetics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chiba City, Chiba, 260-8670 (Japan)
  • 3. Research Center for Allergy and Clinical Immunology, Asahi General Hospital, Chiba (Japan)
  • 4. GeneCare Research Institute Co., Ltd., Kanagawa (Japan)

Description

Asthma is characterized by airway inflammation with intense eosinophil infiltration and mucus hyper-production, in which antigen-specific Th2 cells play critical roles. Nuclear factor-κB (NF-κB) pathway has been demonstrated to be essential for the production of Th2 cytokines and chemokines in the airways in murine asthma models. In the present study, we examined the effect of GS143, a novel small-molecule inhibitor of IκB ubiquitination, on antigen-induced airway inflammation and Th2 cytokine production in mice. Intranasal administration of GS143 prior to antigen challenge suppressed antigen-induced NF-κB activation in the lung of sensitized mice. Intranasal administration of GS143 also inhibited antigen-induced eosinophil and lymphocyte recruitment into the airways as well as the expression of Th2 cytokines and eotaxin in the airways. Moreover, GS143 inhibited antigen-induced differentiation of Th2 cells but not of Th1 cells in vitro. Taken together, these results suggest that IκB ubiquitination inhibitor may have therapeutic potential against asthma

Availability note (English)

Available from http://dx.doi.org/10.1016/j.bbrc.2008.07.072

Additional details

Identifiers

DOI
10.1016/j.bbrc.2008.07.072;
PII
S0006-291X(08)01390-9;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
374
Journal Issue
3
Journal Page Range
p. 507-511
ISSN
0006-291X
CODEN
BBRCA9

Optional Information

Copyright
Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.